The market for diabetes treatments related to SGLT-2 inhibitors has grown by 16% in a year. Analysts say that the use of this drug in the diabetes treatment market is steadily expanding and that major drugs have recently added indications for heart failure treatment, leading to the expansion of appearance. In the first half of next year, Daewoong Pharmaceutical's new SGLT-2 inhibitor-based diabetes drug is expected to launch, which is expected to intensify competition in the market in the future.

◆SGLT-2 Diabetes Treatment Market Expanded by 15%

According to UBIST, a pharmaceutical market research firm, the domestic SGLT-2 inhibitor market in the third quarter of this year was 44.6